{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:44Z","timestamp":1790834324554,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"DOI":"10.1007\/s00044-026-03622-6","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:08:46Z","timestamp":1790831326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vepdegestrant: the first FDA-approved oral PROTAC and a milestone in targeted protein degradation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-1464","authenticated-orcid":false,"given":"Jeffrey","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5652","authenticated-orcid":false,"given":"Longqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"9","key":"3622_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai JM, Nowak RP, Ebert BL, Fischer ES. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol. 2024;25(9):740\u201357. https:\/\/doi.org\/10.1038\/s41580-024-00729-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"3622_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025;25(7):493\u2013516. https:\/\/doi.org\/10.1038\/s41568-025-00817-8.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"3622_CR3","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98(15):8554\u20139. https:\/\/doi.org\/10.1073\/pnas.141230798.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3622_CR4","unstructured":"Food US, Administration D. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Published May 1, 2026. Accessed August 30, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast"},{"issue":"16","key":"3622_CR5","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, B\u00e9k\u00e9s M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res. 2024;30(16):3549\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3622_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","volume":"10","author":"A Pike","year":"2026","unstructured":"Pike A, Lee ECY, Michaelides IN, Schade M, Sharma A, Scott JS, Srivastava A. Lessons learned in linking PROTACs from discovery to the clinic. Nat Rev Chem. 2026;10(2):117\u201332. https:\/\/doi.org\/10.1038\/s41570-025-00784-6.","journal-title":"Nat Rev Chem"},{"issue":"15","key":"3622_CR7","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","volume":"67","author":"M Schade","year":"2024","unstructured":"Schade M, Scott JS, Hayhow TG, Pike A, Terstiege I, Ahlqvist M, Johansson JR, Diene CR, Fallan C, Balazs AYS, Chiarparin E, Wilson D. Structural and physicochemical features of oral PROTACs. J Med Chem. 2024;67(15):13106\u201316. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01017.","journal-title":"J Med Chem"},{"issue":"17","key":"3622_CR8","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.3390\/molecules29174048","volume":"29","author":"H-I Choi","year":"2024","unstructured":"Choi H-I, Choi J, Kim JW, Lee YH, Cho KH, Koo T-S. Stability evaluation and pharmacokinetic profiling of vepdegestrant in rodents using liquid chromatography-tandem mass spectrometry. Molecules. 2024;29(17):4048. https:\/\/doi.org\/10.3390\/molecules29174048.","journal-title":"Molecules"},{"key":"3622_CR9","unstructured":"Food US, and Drug Administration. VEPPANU (vepdegestrant) tablets, for oral use: full prescribing information. Published May 1, 2026. Accessed August 30, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219835Orig1s000lbl.pdf"},{"issue":"6","key":"3622_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, Laurentiis MD, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier M-A, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393(6):556\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2505725.","journal-title":"N Engl J Med"},{"key":"3622_CR11","unstructured":"U.S. Food and Drug Administration. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Published January 27, 2023. Accessed September 06, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer"},{"issue":"28","key":"3622_CR12","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, S\u00e1enz JAG, Bria E, Cazzaniga M, Lu J, Aftimos P, Cort\u00e9s J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356. https:\/\/doi.org\/10.1200\/jco.22.00338.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3622_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1634\/theoncologist.7-6-477","volume":"7","author":"PF Bross","year":"2002","unstructured":"Bross PF, Cohen MH, Williams GA, Pazdur R. FDA drug approval summaries: fulvestrant. Oncologist. 2002;7(6):477\u201380. https:\/\/doi.org\/10.1634\/theoncologist.7-6-477.","journal-title":"Oncologist"},{"issue":"8","key":"3622_CR14","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","volume":"69","author":"W Peng","year":"2026","unstructured":"Peng W, Pan X, Wang S, Huang G, Qian Y. New PROTAC designs for targeted protein degradation in 2021\u20132025: novel E3 ligases and pre-PROTACs. J Med Chem. 2026;69(8):8688\u2013718. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03330.","journal-title":"J Med Chem"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03622-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:08:48Z","timestamp":1790831328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03622-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":14,"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03622-6","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"31 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}